Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32014125

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Haematol
Publication date
2020 Mar
First author
Gisslinger H

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Haematol. 2020 Apr;7(4):e279. doi: 10.1016/S2352-3026(20)30069-7.
    note
    Source null
    related pmid
    32109379
    relationship
    Erratum in

Authors and identifiers

  1. name
    Gisslinger H
    type
    Author
  2. name
    Klade C
    type
    Author
  3. name
    Georgiev P
    type
    Author
  4. name
    Krochmalczyk D
    type
    Author
  5. name
    Gercheva-Kyuchukova L
    type
    Author
  6. name
    Egyed M
    type
    Author
  7. name
    Rossiev V
    type
    Author
  8. name
    Dulicek P
    type
    Author
  9. name
    Illes A
    type
    Author
  10. name
    Pylypenko H
    type
    Author
  11. name
    Sivcheva L
    type
    Author
  12. name
    Mayer J
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Gisslinger H
    type
    Author
  2. name
    Klade C
    type
    Author
  3. name
    Georgiev P
    type
    Author
  4. name
    Krochmalczyk D
    type
    Author
  5. name
    Gercheva-Kyuchukova L
    type
    Author
  6. name
    Egyed M
    type
    Author
  7. name
    Rossiev V
    type
    Author
  8. name
    Dulicek P
    type
    Author
  9. name
    Illes A
    type
    Author
  10. name
    Pylypenko H
    type
    Author
  11. name
    Sivcheva L
    type
    Author
  12. name
    Mayer J
    type
    Author
bibliography ids
  1. nci-bib-e58e1efbd5bdb3ec3723ac5b
book metadata
content sha256
4e69ff1164805c2ea81253589e11420a8fa353c420035ec55b245a8cf5a384c4
document type
citation
dois
  1. 10.1016/S2352-3026(19)30236-4
electronic publication date
display
2020 Jan 31
precision
day
year
2020
evidence scope
bibliographic_metadata_only
id
pubmed:32014125
immutable id
pubmed:32014125@4e69ff1164805c2ea81253589e11420a8fa353c420035ec55b245a8cf5a384c4
journal
abbreviation
Lancet Haematol
issn electronic
2352-3026
issn print
Source null
issue
3
name
The Lancet. Haematology
nlm unique id
101643584
pages
e196-e208
volume
7
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Haematol. 2020 Apr;7(4):e279. doi: 10.1016/S2352-3026(20)30069-7.
    note
    Source null
    related pmid
    32109379
    relationship
    Erratum in
outcomes validated
false
pmid
32014125
provenance
batch id
4c5003fbb78890e89ae1
provider
NCBI PubMed ESummary
record sha256
3ecde0e2c668b6fe3188a7e9d19a4c90304f00b7bff4b861034fff7ace13e50e
response sha256
890389583ce193a9c74e19c63678e418dad2088e82cb704b888b02fcc887d269
retrieved at
2026-09-09T23:47:48.270700+00:00
publication date
display
2020 Mar
precision
month
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/32014125/
title
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

Preserved source evidence · Not medical advice